Phase 1/2 Study of UCART22 for Patients with Difficult-to-Treat CD22+ B-cell Acute Lymphoblastic Leukemia

Sponsor: Cellectis S.A.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04150497

Provider View

This clinical trial is testing a new treatment called UCART22 for patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) that has returned or not responded to previous treatments. The study aims to find out if UCART22 is safe and effective, and to determine the best dose for future studies.

Patient Parameters

Program Overview

This study is the first of its kind to test UCART22, a new treatment given through an IV, in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) that has either come back or not responded to other treatments. The main goals are to check the safety of UCART22, see how well it works, and find the best dose to use in future research.

Eligibility Criteria

Inclusion Criteria

  • Have B-cell Acute Lymphoblastic Leukemia (B-ALL) with cancer cells that show the CD22 marker.
  • Have B-ALL that has returned or not responded to previous treatments.
  • Have already tried at least one standard chemotherapy treatment and one additional treatment after the first one didn't work.

Exclusion Criteria

  • Have received any cellular therapy or experimental gene therapy within 60 days before joining the study.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.